Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Homocystinuria Indication Strategy Report 2026: CBS, Trials and Deals
Latest Hotspot
8 min read
Homocystinuria Indication Strategy Report 2026: CBS, Trials and Deals
21 July 2026
Homocystinuria indication strategy report covering epidemiology, CBS biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Maple syrup urine disease Indication Strategy Report 2026: BCKDHA, Trials and Deals
Latest Hotspot
8 min read
Maple syrup urine disease Indication Strategy Report 2026: BCKDHA, Trials and Deals
21 July 2026
Maple syrup urine disease indication strategy report covering epidemiology, BCKDHA biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Urea cycle disorders Indication Strategy Report 2026: OTCase, Trials and Deals
Latest Hotspot
8 min read
Urea cycle disorders Indication Strategy Report 2026: OTCase, Trials and Deals
21 July 2026
Urea cycle disorders indication strategy report covering epidemiology, OTCase biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Glycogen storage disease type I Indication Strategy Report 2026: G6PC family, Trials and Whitespace
Latest Hotspot
8 min read
Glycogen storage disease type I Indication Strategy Report 2026: G6PC family, Trials and Whitespace
21 July 2026
Glycogen storage disease type I indication strategy report covering epidemiology, G6PC family biology, active trials, competition and deal signals using PatSnap...
Read →
Adult growth hormone deficiency Indication Strategy Report 2026: GHR, Trials and Deals
Latest Hotspot
8 min read
Adult growth hormone deficiency Indication Strategy Report 2026: GHR, Trials and Deals
21 July 2026
Adult growth hormone deficiency indication strategy report covering epidemiology, GHR biology, active trials, competition and deal signals using PatSnap MCP...
Read →
Syndrome of inappropriate antidiuretic hormone secretion Indication Strategy Report 2026: AVPR2, Trials and Deals
Latest Hotspot
8 min read
Syndrome of inappropriate antidiuretic hormone secretion Indication Strategy Report 2026: AVPR2, Trials and Deals
21 July 2026
Syndrome of inappropriate antidiuretic hormone secretion indication strategy report covering epidemiology, AVPR2 biology, active trials, competition and deal...
Read →
Central diabetes insipidus Indication Strategy Report 2026: AVPR2, Trials and Deals
Latest Hotspot
8 min read
Central diabetes insipidus Indication Strategy Report 2026: AVPR2, Trials and Deals
21 July 2026
Central diabetes insipidus indication strategy report covering epidemiology, AVPR2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Hashimoto thyroiditis Indication Strategy Report 2026: TPO, Trials and Deals
Latest Hotspot
8 min read
Hashimoto thyroiditis Indication Strategy Report 2026: TPO, Trials and Deals
21 July 2026
Hashimoto thyroiditis indication strategy report covering epidemiology, TPO biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Graves disease Indication Strategy Report 2026: TSHR, Trials and Deals
Latest Hotspot
8 min read
Graves disease Indication Strategy Report 2026: TSHR, Trials and Deals
21 July 2026
Graves disease indication strategy report covering epidemiology, TSHR biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Hyperthyroidism Indication Strategy Report 2026: TSHR, Trials and Deals
Latest Hotspot
8 min read
Hyperthyroidism Indication Strategy Report 2026: TSHR, Trials and Deals
21 July 2026
Hyperthyroidism indication strategy report covering epidemiology, TSHR biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Hypothalamic obesity Indication Strategy Report 2026: MC4R, Trials and Deals
Latest Hotspot
8 min read
Hypothalamic obesity Indication Strategy Report 2026: MC4R, Trials and Deals
21 July 2026
Hypothalamic obesity indication strategy report covering epidemiology, MC4R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Prader-Willi syndrome Indication Strategy Report 2026: MC4R, Trials and Deals
Latest Hotspot
8 min read
Prader-Willi syndrome Indication Strategy Report 2026: MC4R, Trials and Deals
21 July 2026
Prader-Willi syndrome indication strategy report covering epidemiology, MC4R biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →